1. Home
  2. JANX vs THQ Comparison

JANX vs THQ Comparison

Compare JANX & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.29

Market Cap

890.8M

Sector

Health Care

ML Signal

HOLD

Logo abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

THQ

abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

HOLD

Current Price

$19.04

Market Cap

753.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
JANX
THQ
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
890.8M
753.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
JANX
THQ
Price
$13.29
$19.04
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$57.36
N/A
AVG Volume (30 Days)
1.7M
158.9K
Earning Date
02-26-2026
01-01-0001
Dividend Yield
N/A
7.53%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.12
$15.29
52 Week High
$44.83
$20.38

Technical Indicators

Market Signals
Indicator
JANX
THQ
Relative Strength Index (RSI) 36.48 42.28
Support Level $12.12 $18.82
Resistance Level $14.16 $19.39
Average True Range (ATR) 0.75 0.32
MACD 0.04 -0.11
Stochastic Oscillator 17.66 6.37

Price Performance

Historical Comparison
JANX
THQ

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.

Share on Social Networks: